Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report

The Hallmarks of Cancer

2000 • 27,569 citations

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

2004 • 10,779 citations

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 • 4,992 citations

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

2000 • 3,785 citations

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

2000 • 3,261 citations

Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

2000 • 2,981 citations

FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

2003 • 2,844 citations

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

2004 • 2,481 citations

A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer

2003 • 2,212 citations

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

2004 • 1,935 citations

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

2004 • 1,894 citations

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

2004 • 1,709 citations

Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

2002 • 1,699 citations

Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer

2000 • 1,394 citations

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1998 • 1,273 citations

Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study

2001 • 1,132 citations

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

2005 • 1,081 citations

Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment

2004 • 1,058 citations

Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

2001 • 1,023 citations

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer

1998 • 1,000 citations

Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer.

1998 • 979 citations

Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis

2000 • 943 citations

Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial

2005 • 923 citations

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

1997 • 912 citations

Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial

2003 • 642 citations

XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer

2004 • 520 citations

Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: An Updated Meta-Analysis

2004 • 380 citations

Monoclonal antibodies as therapeutic agents for cancer

2004 • 320 citations

Multicenter Phase II Study of Bimonthly High-Dose Leucovorin, Fluorouracil Infusion, and Oxaliplatin for Metastatic Colorectal Cancer Resistant to the Same Leucovorin and Fluorouracil Regimen

1999 • 287 citations

COX-2 inhibition and colorectal cancer

2004 • 268 citations

Targeted Therapies for Cancer 2004

2004 • 266 citations

Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials

2004 • 256 citations

A Systematic Overview of Chemotherapy Effects in Colorectal Cancer

2001 • 249 citations

Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer

2004 • 234 citations

Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer

2005 • 186 citations

Targeting the epidermal growth factor receptor

2004 • 183 citations

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

2006 • 175 citations

Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952

2003 • 162 citations

A Phase II Study of Troglitazone, an Activator of the PPAR?? Receptor, in Patients with Chemotherapy-Resistant Metastatic Colorectal Cancer

2002 • 156 citations

Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study

2005 • 156 citations

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

2003 • 141 citations

Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin®) and Irinotecan as Therapy. A Phase II Trial

2004 • 133 citations

Pharmacological background of EGFR targeting

2004 • 104 citations

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan

2002 • 103 citations

Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.

2002 • 96 citations

Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin

2004 • 95 citations

New options and old dilemmas in the treatment of patients with advanced colorectal cancer

2004 • 94 citations

Clinical development of gene therapy for colorectal cancer

2003 • 91 citations

A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer

2004 • 88 citations

A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.

2001 • 82 citations

Overview of the clinical efficacy of investigational anticancer drugs

2003 • 81 citations

Multicenter Phase II Study of Nordic Fluorouracil and Folinic Acid Bolus Schedule Combined With Oxaliplatin As First-Line Treatment of Metastatic Colorectal Cancer

2003 • 80 citations

Vascular endothelial growth factor in colorectal cancer

2004 • 75 citations

Monoclonal antibodies in the treatment of colorectal cancer

2004 • 73 citations

A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance

1991 • 72 citations

Randomized Multicenter Phase II Trial of Bolus Plus Infusional Fluorouracil/Leucovorin Compared With Fluorouracil/Leucovorin Plus Oxaliplatin As Third-Line Treatment of Patients With Advanced Colorectal Cancer

2004 • 72 citations

Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects.

2003 • 63 citations

Bolus injection (2–4min) versus short-term (10–20min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial

1998 • 61 citations

2014 Gastrointestinal Cancers Symposium

2014 • 60 citations

Phase II Study of Capecitabine in Patients With Fluorouracil-Resistant Metastatic Colorectal Carcinoma

2004 • 60 citations

Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation

2004 • 50 citations

Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer

2001 • 46 citations

Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301)

2004 • 42 citations

Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin

2004 • 41 citations

Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer

2002 • 37 citations

Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil.

1994 • 37 citations

Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups

2004 • 35 citations

Targeted therapy in advanced colon cancer: the role of new therapies

2004 • 33 citations

The Annual Meeting of the American Society of Clinical Oncology

2010 • 31 citations

Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)

2004 • 31 citations

A Prospective Study of the Use of Chemotherapy in Sweden and Assessment of the Use in Relation to Scientific Evidence

2001 • 30 citations

Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation

2004 • 28 citations

Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab

2004 • 24 citations

Short-Time Infusion of Oxaliplatin (Eloxatin®) in Combination with Capecitabine (Xeloda®) in Patients with Advanced Colorectal Cancer

2003 • 22 citations

Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups

2004 • 20 citations

Palliative Treatment of Patients with Colorectal Cancer

2003 • 16 citations

Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery

2004 • 14 citations

Current perspectives in the treatment of metastatic colorectal cancer

2004 • 13 citations

Current controversies in the adjuvant therapy of colon cancer

2004 • 12 citations

Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) does not increase the incidence of venous thromboembolism when added to first-line chemotherapy to treat metastatic colorectal cancer

2004 • 12 citations

Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis

2004 • 11 citations

Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301)

2004 • 10 citations

First-line treatment options for patients with metastatic colorectal cancer

2004 • 3 citations

Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): Results of an interim safety and efficacy analysis

2005 • 3 citations

A case for time to tumor progression (TTP) as the primary (1^o) efficacy endpoint in 1^st-line metastatic colorectal cancer (MCRC) therapy: Correlation of TTP and overall survival (OS)

2004 • 3 citations

A case for time to tumor progression (TTP) as the primary (1^o) efficacy endpoint in 1^st-line metastatic colorectal cancer (MCRC) therapy: Correlation of TTP and overall survival (OS)

2004 • 2 citations

Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery

2004 • 2 citations

A phase II trial of second-line irinotecan and capecitabine after failure of first line infusional 5-fluorouracil and folinic acid in metastatic colorectal cancer (MCRC)

2004 • 2 citations